1. Home
  2. CTKB vs MLYS Comparison

CTKB vs MLYS Comparison

Compare CTKB & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTKB
  • MLYS
  • Stock Information
  • Founded
  • CTKB 1990
  • MLYS 2019
  • Country
  • CTKB United States
  • MLYS United States
  • Employees
  • CTKB N/A
  • MLYS N/A
  • Industry
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CTKB Health Care
  • MLYS Health Care
  • Exchange
  • CTKB Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • CTKB 450.9M
  • MLYS 1.0B
  • IPO Year
  • CTKB 2021
  • MLYS 2023
  • Fundamental
  • Price
  • CTKB $3.76
  • MLYS $14.54
  • Analyst Decision
  • CTKB Hold
  • MLYS Strong Buy
  • Analyst Count
  • CTKB 4
  • MLYS 4
  • Target Price
  • CTKB $6.00
  • MLYS $27.00
  • AVG Volume (30 Days)
  • CTKB 1.5M
  • MLYS 862.9K
  • Earning Date
  • CTKB 08-05-2025
  • MLYS 08-12-2025
  • Dividend Yield
  • CTKB N/A
  • MLYS N/A
  • EPS Growth
  • CTKB N/A
  • MLYS N/A
  • EPS
  • CTKB N/A
  • MLYS N/A
  • Revenue
  • CTKB $197,050,000.00
  • MLYS N/A
  • Revenue This Year
  • CTKB $0.91
  • MLYS N/A
  • Revenue Next Year
  • CTKB $7.75
  • MLYS N/A
  • P/E Ratio
  • CTKB N/A
  • MLYS N/A
  • Revenue Growth
  • CTKB N/A
  • MLYS N/A
  • 52 Week Low
  • CTKB $2.37
  • MLYS $8.24
  • 52 Week High
  • CTKB $7.63
  • MLYS $18.38
  • Technical
  • Relative Strength Index (RSI)
  • CTKB 64.42
  • MLYS 47.97
  • Support Level
  • CTKB $3.38
  • MLYS $13.22
  • Resistance Level
  • CTKB $3.65
  • MLYS $14.54
  • Average True Range (ATR)
  • CTKB 0.22
  • MLYS 0.71
  • MACD
  • CTKB 0.05
  • MLYS 0.00
  • Stochastic Oscillator
  • CTKB 93.48
  • MLYS 68.37

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: